Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
News|Videos|March 12, 2025
RX Review: Emerging research shaping the future of food allergy care in 2025
In the final part of this 5-part series, panelists discuss new allergy treatments such as Xolair, early immunotherapy, and their broader impact.
Advertisement
Advertisement
Emerging research in food allergy and anaphylaxis is set to reshape clinical practice. In this Contemporary Pediatrics and HCPLive RX Review discussion, moderator Brian Schroer, MD, discusses key advancements with Colleen Kraft, MD, and Russell Traister, MD.
Related to this article
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
Lavengratinib increased annualized height velocity in 7 children with achondroplasia, but open-label phase 2 findings remain preliminary.
The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Advertisement
Advertisement